

Other adverse experiences which were not clearly dose related but which were reported with an incidence greater than 1.0% in placebo-controlled clinical trials include the following:

Placebo-Controlled Studies

Adverse Event	amlodipine (%) (N=1730)	Placebo (%) (N=1250)
Headache	7.3	7.8
Fatigue	4.5	2.8
Nausea	2.9	1.9
Abdominal Pain	1.6	0.3
Somnolence	1.4	0.6

For several adverse experiences that appear to be drug and dose related, there was a greater incidence in women than men associated with amlodipine treatment as shown in the following table:

Adverse Event	amlodipine		Placebo	
	M=% (N=1218)	F=% (N=512)	M=% (N=914)	F=% (N=336)
Edema	5.6	14.6	1.4	5.1
Flushing	1.5	4.5	0.3	0.9
Palpitations	1.4	3.3	0.9	0.9
Somnolence	1.3	1.6	0.8	0.3

The following events occurred in $\leq 1\%$ but $>0.1\%$ of patients treated with amlodipine in controlled clinical trials or under conditions of open trials or marketing experience where a causal relationship is uncertain; they are listed to alert the physician to a possible relationship: **Cardiovascular:** arrhythmia (including ventricular tachycardia and atrial fibrillation), bradycardia, chest pain, hypotension, peripheral ischemia, syncope, tachycardia, postural dizziness, postural hypotension, vasculitis. **Central and Peripheral Nervous System:** hypoesthesia, neuropathy peripheral, paresthesia, tremor, vertigo. **Gastrointestinal:** anorexia, constipation, dyspepsia, dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia. **General:** allergic reaction, asthenia, back pain, hot flashes, malaise, pain, rigors, weight gain, weight decrease. **Musculoskeletal System:** arthralgia, arthrosis, muscle cramps, myalgia. **Psychiatric:** sexual dysfunction (male** and female), insomnia, nervousness, depression, abnormal dreams, anxiety, depersonalization. **Respiratory System:** dyspnea, epistaxis. **Skin and Appendages:** angioedema, erythema multiforme, pruritus, rash, rash erythematous, rash maculopapular. **Special Senses:** abnormal vision, conjunctivitis, diplopia, eye pain, tinnitus. **Urinary System:** micturition frequency, micturition disorder, nocturia. **Autonomic Nervous System:** dry mouth, sweating increased. **Metabolic and Nutritional:** hyperglycemia, thirst. **Hemopoietic:** leukopenia, purpura, thrombocytopenia. The following events occurred in $\leq 0.1\%$ of patients treated with amlodipine in controlled clinical trials or under conditions of open trials or marketing experience: cardiac failure, pulse irregularity, extrasystoles, skin discoloration, urticaria, skin dryness, alopecia, dermatitis, muscle weakness, twitching, ataxia, hypertension, migraine, cold and clammy skin, apathy, agitation, amnesia, gastritis, increased appetite, loose stools, coughing, rhinitis, dysuria, polyuria, parosmia, taste perversion, abnormal visual accommodation, and xerophthalmia. Other reactions occurred sporadically and cannot be distinguished from medications or concurrent disease states such as myocardial infarction and angina. Amlodipine therapy has not been associated with clinically significant changes in routine laboratory tests. No clinically relevant changes were noted in serum potassium, serum glucose, total triglycerides, total cholesterol, HDL cholesterol, uric acid, blood urea nitrogen, or creatinine. In the CAMELOT and PREVENT studies the adverse event profile was similar to that reported previously (see above), with the most common adverse event being peripheral edema. The following postmarketing event has been reported infrequently with amlodipine treatment where a causal relationship is uncertain: gynecomastia. In postmarketing experience, jaundice and hepatic enzyme elevations (mostly consistent with cholestasis or hepatitis) in some cases severe enough to require hospitalization have been reported in association with use of amlodipine. Amlodipine has been used safely in patients with chronic obstructive pulmonary disease, well-compensated congestive heart failure, peripheral vascular disease, diabetes mellitus, and abnormal lipid profiles. **The Atorvastatin Component of CADUET:** Atorvastatin is generally well-tolerated. Adverse reactions have usually been mild and transient. In controlled clinical studies of 2502 patients, $<2\%$ of patients were discontinued due to adverse experiences attributable to atorvastatin calcium. The most frequent adverse events thought to be related to atorvastatin calcium were constipation, flatulence, dyspepsia, and abdominal pain. **Clinical Adverse Experiences:** Adverse experiences reported in $<2\%$ of patients in placebo-controlled clinical studies of atorvastatin, regardless of causality assessment, are shown in Table 3.

Table 3. Adverse Events in Placebo-Controlled Studies (% of Patients)

Body System/ Adverse Event	Placebo N=270	atorvastatin			
		10 mg N=863	20 mg N=36	40 mg N=79	80 mg N=94
BODY AS A WHOLE					
Infection	10.0	10.3	2.8	10.1	7.4
Headache	7.0	5.4	16.7	2.5	6.4
Accidental Injury	3.7	4.2	0.0	1.3	3.2
Flu Syndrome	1.9	2.2	0.0	2.5	3.2
Abdominal Pain	0.7	2.8	0.0	3.8	2.1
Back Pain	3.0	2.8	0.0	3.8	1.1
Allergic Reaction	2.6	0.9	2.8	1.3	0.0
Asthenia	1.9	2.2	0.0	3.8	0.0
DIGESTIVE SYSTEM					
Constipation	1.8	2.1	0.0	2.5	1.1
Diarrhea	1.5	2.7	0.0	3.8	5.3
Dyspepsia	4.1	2.3	2.8	1.3	2.1
Flatulence	3.3	2.1	2.8	1.3	1.1
RESPIRATORY SYSTEM					
Sinusitis	2.6	2.8	0.0	2.5	6.4
Pharyngitis	1.5	2.5	0.0	1.3	2.1
SKIN AND APPENDAGES					
Rash	0.7	3.9	2.8	3.8	1.1
MUSCULOSKELETAL SYSTEM					
Arthralgia	1.5	2.0	0.0	5.1	0.0
Myalgia	1.1	3.2	5.6	1.3	0.0

Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT): In ASCOT involving 10,305 participants treated with atorvastatin 10 mg daily (n=5,168) or placebo (n=5,137), the safety and tolerability profile of the group treated with atorvastatin was comparable to that of the group treated with placebo during a median of 3.3 years of follow-up. **Collaborative Atorvastatin Diabetes Study (CARDS):** In CARDS involving 2838 subjects with type 2 diabetes treated with LIPITOR 10 mg daily (n=1428) or placebo (n=1410), there was no difference in the overall frequency of adverse events or serious adverse events between the treatment groups during a median follow-up of 3.9 years. No cases of rhabdomyolysis were reported. The following adverse events were reported, regardless of causality assessment, in patients treated with atorvastatin in clinical trials. The events in italics occurred in $\geq 2\%$ of patients and the events in plain type occurred in $<2\%$ of patients. **Body as a Whole:** Chest pain, face edema, fever, neck rigidity, malaise, photosensitivity reaction, generalized edema. **Digestive System:** Nausea, gastroenteritis, liver function tests abnormal, colitis, vomiting, gastritis, dry mouth, rectal hemorrhage, esophagitis, eructation, glossitis, mouth ulceration, anorexia, increased appetite, stomatitis, biliary pain, chills, duodenal ulcer, dysphagia, enteritis, melena, gum hemorrhage, stomach ulcer, tenesmus, ulcerative stomatitis, hepatitis, pancreatitis, cholestatic jaundice. **Respiratory System:** Bronchitis, rhinitis, pneumonia, dyspnea, asthma, epistaxis. **Nervous System:** Insomnia, dizziness, paresthesia, somnolence, amnesia, abnormal dreams, libido decreased, emotional lability, incoordination, peripheral neuropathy, torticollis, facial paralysis, hyperkinesia, depression, hypesthesia, hypertonia. **Musculoskeletal System:** Arthritis, leg cramps, bursitis, tenosynovitis, myasthenia, tendinous contracture, myositis. **Skin and Appendages:** Pruritus, contact dermatitis, alopecia, dry skin, sweating, acne, urticaria, eczema, seborrhea, skin ulcer. **Urogenital System:** Urinary tract infection, hematuria, albuminuria, urinary frequency, cystitis, impotence, dysuria, kidney calculus, nocturia, epididymitis, fibrocystic breast, vaginal hemorrhage, breast enlargement, metrorrhagia, nephritis, urinary incontinence, urinary retention, urinary urgency, abnormal ejaculation, uterine hemorrhage. **Special Senses:** Amblyopia, tinnitus, dry eyes, refraction disorder, eye hemorrhage, deafness, glaucoma, parosmia, taste loss, taste perversion. **Cardiovascular System:** Palpitation, vasodilatation, syncope, migraine, postural hypotension, phlebitis, arrhythmia, angina pectoris, hypertension. **Metabolic and Nutritional Disorders:** Peripheral edema, hyperglycemia, creatine phosphokinase increased, gout, weight gain, hypoglycemia. **Hemic and Lymphatic System:** Echinomycosis, anemia, lymphadenopathy, thrombocytopenia, petechia. **Postintroduction Reports with Atorvastatin:** Adverse events associated with atorvastatin therapy reported since market introduction, that are not listed above, regardless of causality assessment, include the following: anaphylaxis, angioneurotic edema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rhabdomyolysis, and fatigue, and tendon rupture. **Pediatric Patients (ages 10-17 years):** In a 26-week controlled study in boys and postmenarcheal girls (n=140), the safety and tolerability profile of atorvastatin 10 to 20 mg daily was generally similar to that of placebo (see PRECAUTIONS, Pediatric Use).

OVERDOSAGE: There is no information on overdosage with CADUET in humans. **Information on Amlodipine:** Single oral doses of amlodipine maleate equivalent to 40 mg amlodipine/kg and 100 mg amlodipine/kg in mice and rats, respectively, caused deaths. Single oral amlodipine maleate doses equivalent to 4 or more mg amlodipine/kg in dogs (11 or more times the maximum recommended clinical dose on a mg/m² basis) caused a marked peripheral vasodilation and hypotension. Overdosage might be expected to cause excessive peripheral vasodilation with marked hypotension and possibly a reflex tachycardia. In humans, experience with intentional overdosage of amlodipine is limited. Reports of intentional overdosage include a patient who ingested 250 mg and was asymptomatic and was not hospitalized; another (120 mg) was hospitalized, underwent gastric lavage and remained normotensive; the third (105 mg) was hospitalized and had hypotension (90/50 mmHg) which normalized following plasma expansion. A patient who took 70 mg amlodipine and an unknown quantity of benzodiazepine in a suicide attempt developed shock which was refractory to treatment and died the following day with abnormally high benzodiazepine plasma concentration. A case of accidental drug overdose has been documented in a 19-month-old male who ingested 30 mg amlodipine (about 2 mg/kg). During the emergency room presentation, vital signs were stable with no evidence of hypotension, but a heart rate of 180 bpm. Ipecac was administered 3.5 hours after ingestion and on subsequent observation (overnight) no sequelae were noted. If massive overdose should occur, active cardiac and respiratory monitoring should be instituted. Frequent blood pressure measurements are essential. Should hypotension occur, cardiovascular support including elevation of the extremities and the judicious administration of fluids should be initiated. If hypotension remains unresponsive to these conservative measures, administration of vasopressors (such as phenylephrine) should be considered with attention to circulating volume and urine output. Intravenous calcium gluconate may help to reverse the effects of calcium entry blockade. As amlodipine is highly protein bound, hemodialysis is not likely to be of benefit. **Information on Atorvastatin:** There is no specific treatment for atorvastatin overdosage. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required. Due to extensive drug binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.

*Based on patient weight of 50 kg.

**These events occurred in less than 1% in placebo-controlled trials, but the incidence of these side effects was between 1% and 2% in all multiple dose studies.

R only

Manufactured by:
Pfizer Ireland Pharmaceuticals
Dublin, Ireland



Distributed by:
Pfizer Labs
Division of Pfizer Inc., NY, NY 10017

© 2006 Pfizer Ireland Pharmaceuticals

Revised December 2006

CTU00116D

© 2007 Pfizer Inc.

All rights reserved.

May 2007



U.S. Pharmaceuticals

Cardiologist Follow-Up Lacking in CHD Patients

BY MITCHEL L. ZOLER

Philadelphia Bureau

NEW ORLEANS — Patients with congenital heart disease often fail to get the cardiology follow-up they need, on the basis of the records of 643 patients from Canada who were followed through age 22.

Although “most congenital heart disease [CHD] lesions require life-long cardiology follow-up,” this follow-up was not seen for 61% of all the CHD patients in this representative group once they were 18-22 years old, and cardiology follow-up did not occur at age 18-22 for 34% of the patients with “severe” CHD lesions, Dr. Andrew S. Mackie said at the annual meeting of the American College of Cardiology.

Cardiology follow-up was often lacking even though these patients remained under ongoing medical care. The analysis showed that 87% of all of the CHD patients followed were seen by a primary care physician at least once when they were 18-22 years old. A better job must be done to educate primary care physicians that patients with CHD require ongoing follow-up by a cardiologist, said Dr. Mackie, a cardiologist at Montreal Children’s Hospital.

“These patients must be seen by a cardiologist,” agreed Dr. Joseph K. Perloff, a

CHD specialist and emeritus professor of medicine and pediatrics at the University of California, Los Angeles.

The study used data from the Canadian health insurance system to identify and track 643 people who were born in the province of Quebec in 1983, were diagnosed with a CHD before age 6, and were still alive in 2005. All were seen by a cardiologist at least once when they were age 0-5, when they were first diagnosed. The analysis then used Canadian medical records to identify their visits to cardiologists and primary care physicians during three stages: age 6-12, 13-17, and 18-22.

Virtually all of the patients were seen by a primary care physician—a pediatrician, family practice physician, or internist—at least once during each of these life stage. But substantially fewer had at least one follow-up examination by a cardiologist, even at age 6-12. Among the 122 patients (19%) with severe CHD—endocardial cushion defect, tetralogy of Fallot, a univentricular heart, transposition of the great arteries, truncus arteriosus, and hypoplastic left heart syndrome—a higher proportion were followed by a cardiologist, but even in this subgroup expert follow-up was lacking for a significant number of patients, Dr. Mackie said. ■

Congenital Heart Disease Patients Are Living Longer

BY MITCHEL L. ZOLER

Philadelphia Bureau

NEW ORLEANS — Over the past 2 decades, patients with congenital heart disease have increasingly lived to an older age, according to data collected on about 70,000 CHD patients living in Quebec.

The rising age of death has been most dramatic among children younger than 10, probably because of improved surgical management of severe congenital heart defects, Dr. Paul Khairy said at the annual meeting of the American College of Cardiology. During 1988-1989, the median age of death was 8 years among patients with severe CHD in Quebec (except those younger than 1 year). By 2004-2005, the median age of death in this group had soared to 42 years, said Dr. Khairy, a cardiologist and epidemiologist at the Montreal Heart Institute.

Because of these changes in mortality, “the burden of CHD has shifted to older patients,” he said.

His analysis used data collected on the more than 70,000 Quebec residents with a diagnosed CHD who were at least 1 year old and alive for some period in 1988-2005.

The analysis then focused on the 45,651 people with CHD alive during 1988-1989, and the 62,052 alive with CHD during 2004-2005. The overall mortality of these patients was 4.6/1,000 patients in 1988-1989, and 10.3/1,000 patients in 2004-2005.

A breakdown of death rates by age showed a pronounced bimodal distribution in 1988-1989, with one peak occurring among children aged 10 and younger and the second peak occurring at age 61-76. During this year, about 13% of deaths among all people with CHD occurred among children aged 1-5, and about 8% of the deaths were in children aged 6-10. In contrast, the early childhood peak had largely disappeared by 2004-2005. During that year, about 3% of the deaths were in children aged 1-5, and about 1% were in those aged 6-10. The mortality pattern by age in patients with CHD during 2004-2005 was similar to the pattern for the overall Quebec population, with the peak age of death occurring at about 71-90 years, Dr. Khairy said.

Another analysis focused on the patients with severe forms of CHD, defined as an endocardial cushion defect, tetralogy of Fallot, a univentricular heart, transposition of the great arteries, truncus arteriosus, and hypoplastic left heart syndrome. In this subgroup, the mortality rate was about 43% among children aged 1-4 in 1988-1989; the rate dropped to about 10% by 2004-2005. Among children aged 5-9, mortality was about 18% in 1988-1989, falling to about 7% in 2004-2005. The overall median age of death in all patients with CHD was 61 years in 1988-1989 and 68 years in 2004-2005, a statistically significant increase, Dr. Khairy said. ■